Upregulation of miR-1199-5p Is Associated With Reduced Type 2 5-Alpha Reductase Expression in Benign Prostatic Hyperplasia

The study explored the role of miR-1199-5p in regulating the expression of type 2 5-α reductase (SRD5A2) in benign prostatic hyperplasia (BPH) and its potential impact on the effectiveness of 5-α reductase inhibitor (5-ARI) therapy. It was found that miR-1199-5p was significantly upregulated in BPH tissues with negative or weak SRD5A2 expression, suggesting that miR-1199-5p might contribute to the variability in SRD5A2 expression. This upregulation was associated with decreased sensitivity to finasteride, a 5-ARI, indicating that miR-1199-5p could be a factor in the resistance to 5-ARI therapy. The study involved 59 BPH specimens and highlighted the need for further research due to limitations such as a small sample size and the inclusion of patients previously treated with 5-ARIs.